Tenofovir (all routes except local)

Elective/induced termination of pregnancy

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S5134
R13392
Floridia, 2018 Voluntary termination of pregnancy during pregnancy (anytime or not specified) cohort exposed to other treatment, sick Adjustment: No Control group: Abacavir/Lamivudine-based Exposed group: TDF/emtricitabine-based Indication: HIV 1.37 [0.73;2.58] C 41/442   14/202 55 442
ref
S5265
R13634
Mugo, 2014 Induced pregnancy losses early pregnancy randomized controlled trial unexposed, sick Adjustment: Randomisation Control group: Unexposed, sick Exposed group: TDF (only) Indication: PrEP 1.11 [0.46;2.71] C 16/174   8/96 24 174
ref
Total 2 studies 1.28 [0.77;2.14] 79 616
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Floridia, 2018Floridia, 2018 1.37[0.73; 2.58]5544266%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Mugo, 2014Mugo, 2014 1.11[0.46; 2.71]2417434%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.28[0.77; 2.14]796160.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.28[0.77; 2.14]796160%NAFloridia, 2018 Mugo, 2014 2 case control studiescase control studies 0 RCTRCT 1.11[0.46; 2.71]24174 -NAMugo, 2014 1 Type of controls unexposed, sickunexposed, sick 1.11[0.46; 2.71]24174 -NAMugo, 2014 1 exposed to other treatment, sickexposed to other treatment, sick 1.37[0.73; 2.58]55442 -NAFloridia, 2018 1 Tags Adjustment   - No  - No 1.37[0.73; 2.58]55442 -NAFloridia, 2018 1   - Randomisation  - Randomisation 1.11[0.46; 2.71]24174 -NAMugo, 2014 1 Control group   - Abacavir/Lamivudine-based  - Abacavir/Lamivudine-based 1.37[0.73; 2.58]55442 -NAFloridia, 2018 1   - Unexposed, sick  - Unexposed, sick 1.11[0.46; 2.71]24174 -NAMugo, 2014 1 Exposed group   - TDF (only)  - TDF (only) 1.11[0.46; 2.71]24174 -NAMugo, 2014 1   - TDF/emtricitabine-based  - TDF/emtricitabine-based 1.37[0.73; 2.58]55442 -NAFloridia, 2018 1 Indication   - HIV  - HIV 1.37[0.73; 2.58]55442 -NAFloridia, 2018 1   - PrEP  - PrEP 1.11[0.46; 2.71]24174 -NAMugo, 2014 1 All studiesAll studies 1.28[0.77; 2.14]796160%NAFloridia, 2018 Mugo, 2014 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.11[0.46; 2.71]24174 -NAMugo, 2014 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.37[0.73; 2.58]55442 -NAFloridia, 2018 10.510.01.0